- Recent retrospective cohort study of 13,108 adults found no increased risk of major adverse cardiovascular events following exposure to nicotinamide.
- No statistically significant difference in major adverse cardiovascular events (MACE) incidence between nicotinamide users and non-users.
- Stratified analyses found no significant association between nicotinamide exposure and MACE among immunosuppressed patients.
- The study addresses concerns raised by previous research and has clinical implications for patients using nicotinamide for skin cancer chemoprevention, particularly high-risk groups such as organ transplant recipients.
- Authors acknowledge limitations including the predominantly male veteran population in the MVP cohort.
No Increased Cardiovascular Risk with Nicotinamide Use: Study
Conexiant
March 14, 2025
